Posted On: 11/14/2016 5:24:46 PM
Post# of 72447
Re: someconcerns #28877
You are welcome! Some tidbits from the update:
Brilacidin (Inflammatory Bowel Disease)
- The final two patients in the first cohort are currently receiving Brilacidin therapy
- Completion of the first cohort and start of second cohort is anticipated in December 2016
Brilacidin-OM (Oral Mucositis)
- Interim analysis anticipated 1H 2017
Brilacidin (Anti-Infective)
- Now working with U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) agreement – will be positioned to move into Phase 3 research upon finalizing SPA and securing funding as to not impede other pipeline developments
Kevetrin (Solid Tumors)
- Now preparing for Phase 2a study to better define the mechanism of action of Kevetrin, specifically the modulation of p53 within the tumor
- Phase 2a trial planned to be initiated
Prurisol (Chronic Plaque Psoriasis)
-Interim analysis from the Phase 2b trial expected 1H 2017
"We have yet to fail in any clinical trial with any of our drug candidates and remain on target with our long-term goal to grow shareholder value by developing our drugs for hard-to-treat indications to provide relief for millions of people suffering worldwide."
Brilacidin (Inflammatory Bowel Disease)
- The final two patients in the first cohort are currently receiving Brilacidin therapy
- Completion of the first cohort and start of second cohort is anticipated in December 2016
Brilacidin-OM (Oral Mucositis)
- Interim analysis anticipated 1H 2017
Brilacidin (Anti-Infective)
- Now working with U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) agreement – will be positioned to move into Phase 3 research upon finalizing SPA and securing funding as to not impede other pipeline developments
Kevetrin (Solid Tumors)
- Now preparing for Phase 2a study to better define the mechanism of action of Kevetrin, specifically the modulation of p53 within the tumor
- Phase 2a trial planned to be initiated
Prurisol (Chronic Plaque Psoriasis)
-Interim analysis from the Phase 2b trial expected 1H 2017
"We have yet to fail in any clinical trial with any of our drug candidates and remain on target with our long-term goal to grow shareholder value by developing our drugs for hard-to-treat indications to provide relief for millions of people suffering worldwide."
(2)
(0)
